Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
Type:
Grant
Filed:
August 26, 2014
Date of Patent:
November 3, 2015
Assignee:
Astar Biotech LLC
Inventors:
Chunrong Yu, Haihong Huang, Dongfeng Zhang, Peng Li
Abstract: A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit.
Type:
Grant
Filed:
January 5, 2012
Date of Patent:
January 20, 2015
Assignees:
Astar Biotech LLC, Beta Pharma Canada Inc.
Abstract: The present invention relates to compounds of Formula VIII with absolute configuration R or S: as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula VIII, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
Type:
Application
Filed:
August 26, 2014
Publication date:
December 11, 2014
Applicant:
ASTAR BIOTECH LLC
Inventors:
Chunrong YU, Haihong HUANG, Dongfeng ZHANG, Peng LI
Abstract: The present invention relates to compounds of Formula I: as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
Type:
Grant
Filed:
July 30, 2012
Date of Patent:
October 14, 2014
Assignee:
Astar Biotech LLC
Inventors:
Chunrong Yu, Haihong Huang, Dongfeng Zhang, Peng Li
Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
Abstract: The present invention relates to compounds of Formula I: as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.
Type:
Application
Filed:
July 30, 2012
Publication date:
January 30, 2014
Applicant:
Astar Biotech LLC
Inventors:
Chunrong YU, Haihong Huang, Dongfeng Zhang, Peng Li
© 2024 Justia
